Literature DB >> 16077186

Lipid signaling in neural plasticity, brain repair, and neuroprotection.

Nicolas G Bazan1.   

Abstract

The extensive networking of the cells of the nervous system results in large cell membrane surface areas. We now know that neuronal membranes contain phospholipid pools that are the reservoirs for the synthesis of specific lipid messengers on neuronal stimulation or injury. These messengers in turn participate in signaling cascades that can either promote neuronal injury or neuroprotection. Prostaglandins are synthesized as a result of cyclooxygenase activity. In the first step of the arachidonic acid cascade, the short-lived precursor, prostaglandin H2, is synthesized. Additional steps in the cascade result in the synthesis of an array of prostaglandins, which participate in numerous physiological and neurological processes. Our laboratory recently reported that the membrane polyunsaturated fatty acid, docosahexaenoic acid, is the precursor of oxygenation products now known as the docosanoids, some of which are powerful counter-proinflammatory mediators. The mediator 10,17S-docosatriene (neuroprotectin D1, NPD1) counteracts leukocyte infiltration, NF-kappa activation, and proinflammatory gene expression in brain ischemia-reperfusion and is an apoptostatic mediator, potently counteracting oxidative stress-triggered apoptotic DNA damage in retinal pigment epithelial cells. NPD1 also upregulates the anti-apoptotic proteins Bcl-2 and Bcl-xL and decreases pro-apoptotic Bax and Bad expression. Another biologically active messenger derived from membrane phospholipids in response to synaptic activity is platelet-activating factor (PAF). The tight regulation of the balance between synthesis (via phospholipases) and degradation (via acetylhydrolases) of PAF modulates the functions of this lipid messenger. Under pathological conditions, this balance is tipped, and PAF becomes a proinflammatory mediator and neurotoxic agent. The newly discovered docosahexaenoic acid signaling pathways, as well as other lipid messengers related to synaptic activation, may lead to the clarification of clinical issues relevant to stroke, age-related macular degeneration, spinal cord injury, Alzheimer's disease, and other diseases that include neuroinflammatory components.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16077186     DOI: 10.1385/MN:32:1:089

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  92 in total

1.  Diets enriched in docosahexaenoic acid fail to correct progressive rod-cone degeneration (prcd) phenotype.

Authors:  G D Aguirre; G M Acland; M B Maude; R E Anderson
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-10       Impact factor: 4.799

Review 2.  Bioactive lipids in excitatory neurotransmission and neuronal plasticity.

Authors:  N G Bazan; M G Packard; L Teather; G Allan
Journal:  Neurochem Int       Date:  1997-02       Impact factor: 3.921

3.  Attenuated LTP in hippocampal dentate gyrus neurons of mice deficient in the PAF receptor.

Authors:  C Chen; J C Magee; V Marcheselli; M Hardy; N G Bazan
Journal:  J Neurophysiol       Date:  2001-01       Impact factor: 2.714

4.  Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger.

Authors:  T J O'Dell; R D Hawkins; E R Kandel; O Arancio
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

5.  Effect of bicuculline-induced status epilepticus on prostaglandins and hydroxyeicosatetraenoic acids in rat brain subcellular fractions.

Authors:  D L Birkle; N G Bazan
Journal:  J Neurochem       Date:  1987-06       Impact factor: 5.372

6.  Transport of 22:6n-3 in the plasma and uptake into retinal pigment epithelium and retina.

Authors:  N Wang; R E Anderson
Journal:  Exp Eye Res       Date:  1993-08       Impact factor: 3.467

7.  Retinal pigment epithelial cells play a central role in the conservation of docosahexaenoic acid by photoreceptor cells after shedding and phagocytosis.

Authors:  W C Gordon; E B Rodriguez de Turco; N G Bazan
Journal:  Curr Eye Res       Date:  1992-01       Impact factor: 2.424

8.  Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression.

Authors:  Victor L Marcheselli; Song Hong; Walter J Lukiw; Xiao Hua Tian; Karsten Gronert; Alberto Musto; Mattie Hardy; Juan M Gimenez; Nan Chiang; Charles N Serhan; Nicolas G Bazan
Journal:  J Biol Chem       Date:  2003-08-15       Impact factor: 5.157

9.  Differential expression of rat and human type I metabotropic glutamate receptor splice variant messenger RNAs.

Authors:  A Berthele; D J Laurie; S Platzer; W Zieglgänsberger; T R Tölle; B Sommer
Journal:  Neuroscience       Date:  1998-08       Impact factor: 3.590

Review 10.  Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor.

Authors:  Nicolas G Bazan
Journal:  J Lipid Res       Date:  2003-09-16       Impact factor: 5.922

View more
  53 in total

1.  Small molecule analysis and imaging of fatty acids in the zebra finch song system using time-of-flight-secondary ion mass spectrometry.

Authors:  Kensey R Amaya; Jonathan V Sweedler; David F Clayton
Journal:  J Neurochem       Date:  2011-05-19       Impact factor: 5.372

Review 2.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

3.  Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain.

Authors:  Yewon Cheon; Jee-Young Park; Hiren R Modi; Hyung-Wook Kim; Ho-Joo Lee; Lisa Chang; Jagadeesh S Rao; Stanley I Rapoport
Journal:  J Neurochem       Date:  2011-09-20       Impact factor: 5.372

4.  LAU-0901, a novel platelet-activating factor antagonist, is highly neuroprotective in cerebral ischemia.

Authors:  Ludmila Belayev; Larissa Khoutorova; Kristal Atkins; William C Gordon; Julio Alvarez-Builla; Nicolas G Bazan
Journal:  Exp Neurol       Date:  2008-08-28       Impact factor: 5.330

5.  Prostaglandin EP2 Receptors Mediate Mesenchymal Stromal Cell-Neuroprotective Effects on Dopaminergic Neurons.

Authors:  Juan Andrés Parga; María García-Garrote; Salvador Martínez; Ángel Raya; José Luis Labandeira-García; Jannette Rodríguez-Pallares
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

6.  LAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat.

Authors:  Ludmila Belayev; Larissa Khoutorova; Kristal Atkins; Alice Cherqui; Julio Alvarez-Builla; Nicolas G Bazan
Journal:  Brain Res       Date:  2008-12-03       Impact factor: 3.252

7.  PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury.

Authors:  Sofiyan Saleem; Hean Zhuang; Artur J de Brum-Fernandes; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Eur J Neurosci       Date:  2007-06-16       Impact factor: 3.386

8.  Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?

Authors:  H-J Lee; J S Rao; L Chang; S I Rapoport; H-W Kim
Journal:  Mol Psychiatry       Date:  2008-11-04       Impact factor: 15.992

9.  PAF-AH Catalytic Subunits Modulate the Wnt Pathway in Developing GABAergic Neurons.

Authors:  Idit Livnat; Danit Finkelshtein; Indraneel Ghosh; Hiroyuki Arai; Orly Reiner
Journal:  Front Cell Neurosci       Date:  2010-05-28       Impact factor: 5.505

10.  Cytosolic phospholipase A2 alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice.

Authors:  Koji Kishimoto; Rung-Chi Li; Jian Zhang; Judith A Klaus; Kathleen K Kibler; Sylvain Doré; Raymond C Koehler; Adam Sapirstein
Journal:  J Neuroinflammation       Date:  2010-07-30       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.